More articles on this subject
Profile picture of ITVX
Baby saved from dead mother's womb after airstrike in Gaza dies: Sabreen Jouda's father and four-year-old sister were also killed.
itv.com/news/2024-04-26/baby-saved-from-dead-mothers-womb-after-airstrike-in-gaza-dies
Baby saved from dead mother's womb after airstrike in Gaza dies
Quick Glance: Premature Baby Rescued from Dead Mother's Womb Dies in Gaza After 5 Days
  • A premature Palestinian infant, rescued from her mother's womb shortly after the woman was killed in an Israeli airstrike, has died, according to her uncle.

  • Sabreen Jouda died in a Gaza hospital after her health deteriorated and medical teams were unable to save her, said her uncle.

  • Following an Israeli airstrike on Sabreen's home in the southern Gaza city of Rafah, her parents and 4-year-old sister tragically lost their lives.

  • More than 34,000 Palestinians have been killed during the Israel-Hamas war, with local health officials stating that about two-thirds of the dead are women and children. Health officials do not differentiate between combatants and civilians in their count.
Profile picture of The Independent
British patients test world’s first personalised MRNA cancer jab for melanoma: The ‘gamechanger’ jab works by telling the body to hunt down cancer cells and ...
independent.co.uk/news/health/mrna-cancer-jab-melanoma-trial-treatment-b2534935.html
British patients test world’s first personalised MRNA cancer jab for ...
Quick Glance: Innovative Cancer Treatment Tested on Melanoma Patient
  • A music teacher with melanoma is among the first to receive a new anti-cancer treatment that shows potential for curing the disease.

  • The personalized mRNA cancer jab instructs the body's immune system to target and eliminate cancer cells, with promising results in reducing cancer recurrence.

  • Conducted by University College London Hospitals, the trial aims to cure melanoma patients and explore its effectiveness in other cancer types.

  • The therapy, tailored to each patient's tumor, marks a significant advancement in cancer treatment, with a global trial expanding to recruit 1,100 participants.